Pharmaceutical Care Program for Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule Objectives:- To evaluate Pharmaceutical care program in Type2 diabetics. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus. To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

Detailed Description
-----------------
To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus. To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Official Title
-----------------
Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule

Conditions
-----------------
DIABETES MELLITUS, TYPE 2

Intervention / Treatment
-----------------
* Other: PHARMACEUTICAL CARE programe
* Other: Without PHARMACEUTICAL CARE programe


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Inclusion Criteria: Patients with type 2 diabetes mellitus of either Patients with HbA1c more than 7% and Patients with blood sugar level more than 140 mg / dl Exclusion Criteria: Patient with end stage kidney disease. Patient with heart failure. Patient with chronic Diabetes problem and orthopedic problem

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PHARMACEUTICAL CARE programe<br>The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems. | Other: PHARMACEUTICAL CARE programe<br>* The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.<br>|
| Other: control<br>without pharmaceutical care programe (control) | Other: Without PHARMACEUTICAL CARE programe<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded | Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded fasting blood glucose | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of Life score | Quality of Life score | 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pharmaceutical care